EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ligand Pharmaceuticals's enterprise value is $1,073.3 Mil.
Ligand Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $100.0 Mil. Therefore, Ligand Pharmaceuticals's EV-to-EBITDA for today is 10.74.
The historical rank and industry rank for Ligand Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
LGND'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.37 Med: 22.03 Max: 344.52
Current: 10.74
During the past 13 years, the highest EV-to-EBITDA of Ligand Pharmaceuticals was 344.52. The lowest was 0.37. And the median was 22.03.
LGND's EV-to-EBITDA is ranked worse than 53.8% of 474
companies
in the Biotechnology industry
Industry Median: 9.165
vs LGND: 10.74
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-24), Ligand Pharmaceuticals's stock price is $69.89.
Ligand Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.900. Therefore, Ligand Pharmaceuticals's PE Ratio for today is 24.10.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Ligand Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for Ligand Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ligand Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ligand Pharmaceuticals EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ligand Pharmaceuticals's EV-to-EBITDA falls into.
Ligand Pharmaceuticals EV-to-EBITDA Calculation
Ligand Pharmaceuticals's EV-to-EBITDA for today is calculated as:
Ligand Pharmaceuticals's current Enterprise Value is $1,073.3 Mil.
Ligand Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $100.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Ligand Pharmaceuticals's PE Ratio for today is calculated as:
Ligand Pharmaceuticals's share price for today is $69.89.
Ligand Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Ligand Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Ligand Pharmaceuticals (Ligand Pharmaceuticals) Business Description
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LGND has been successfully added to your 